Tocilizumab

Generic Name
Tocilizumab
Brand Names
Actemra, RoActemra, Tyenne, Tofidence
Drug Type
Biotech
Chemical Formula
-
CAS Number
375823-41-9
Unique Ingredient Identifier
I031V2H011
Background

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19, tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.

Indication

Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.

Tocilizumab is also used to treat coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Associated Conditions
Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
Monotherapy

Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

First Posted Date
2020-04-09
Last Posted Date
2021-01-11
Lead Sponsor
Hellenic Institute for the Study of Sepsis
Target Recruit Count
102
Registration Number
NCT04339712
Locations
🇬🇷

Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece

🇬🇷

Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece

🇬🇷

Intensive Care Unit, "Latsio", Thriasio Elefsis General Hospital, Elefsína, Greece

and more 14 locations

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

First Posted Date
2020-04-08
Last Posted Date
2024-12-09
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
55
Registration Number
NCT04338685
Locations
🇩🇰

Rigshospitalet; Onkologisk Klinik, København Ø, Denmark

🇺🇸

City of Hope Cancer Center, Duarte, California, United States

🇭🇰

Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong

and more 7 locations

Checkpoint Blockade in COVID-19 Pandemic

First Posted Date
2020-04-06
Last Posted Date
2022-06-21
Lead Sponsor
MedSIR
Target Recruit Count
12
Registration Number
NCT04335305
Locations
🇪🇸

Hospital Arnau de Vilanova-Lliria, Valencia, Spain

🇪🇸

Hospital Quirónsalud Barcelona, Barcelona, Spain

🇪🇸

Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain

and more 4 locations

CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

Phase 2
Conditions
Interventions
First Posted Date
2020-04-02
Last Posted Date
2020-04-28
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
228
Registration Number
NCT04331808
Locations
🇫🇷

APHP- Hopital Tenon, Paris, France

🇫🇷

APHP - Beaujon, Paris, France

🇫🇷

APHP - Hopital Necker, Paris, France

and more 5 locations

Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)

First Posted Date
2020-04-02
Last Posted Date
2021-05-06
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
276
Registration Number
NCT04332094
Locations
🇪🇸

Hospital del Mar, Barcelona, Spain

🇪🇸

Hospital General Universitario de Alicante, Alicante, Valencia, Spain

🇪🇸

Hospital General Universitario de Elche, Elche, Valencia, Spain

and more 4 locations

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-04-02
Last Posted Date
2022-06-09
Lead Sponsor
University of Chicago
Target Recruit Count
32
Registration Number
NCT04331795
Locations
🇺🇸

University of Chicago Medicine, Chicago, Illinois, United States

Treatment of COVID-19 Patients With Anti-interleukin Drugs

First Posted Date
2020-04-01
Last Posted Date
2023-03-14
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
342
Registration Number
NCT04330638
Locations
🇧🇪

University Hospital Antwerp, Edegem, Belgium

🇧🇪

Ziekenhuis Oost-Limurg, Genk, Belgium

🇧🇪

AZ Delta, Roeselare, Belgium

and more 12 locations

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

Phase 2
Conditions
Interventions
First Posted Date
2020-03-19
Last Posted Date
2020-04-13
Lead Sponsor
Università Politecnica delle Marche
Target Recruit Count
38
Registration Number
NCT04315480
Locations
🇮🇹

Università Politecnica delle Marche, Ancona, AN, Italy

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

First Posted Date
2020-03-18
Last Posted Date
2024-03-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
23
Registration Number
NCT04313608
Locations
🇦🇺

Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia

🇦🇺

Monash Health Monash Medical Centre, Clayton, Victoria, Australia

🇦🇺

St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

First Posted Date
2020-03-17
Last Posted Date
2020-04-10
Lead Sponsor
Peking University First Hospital
Target Recruit Count
150
Registration Number
NCT04310228
Locations
🇨🇳

Guiqiang Wang, Beijing, Beijing, China

🇨🇳

Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China

🇨🇳

Jinyintan Hospital of Wuhan, Wuhan, Hubei, China

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath